Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination antifungal therapy for Candida bloodstream infections
ISRCTN56596656Phase 3Not yet recruiting
- Sponsor
- Wits Health Consortium
- Start
- Dec 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of micafungin, flucytosine and fluconazole in candidemia (5 arms), sponsored by Wits Health Consortium. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
micafunginflucytosinefluconazole
03
Conditions
candidemia
Beyond the preview
Go deeper on ISRCTN56596656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN56596656.